Retatrutide is an investigational synthetic peptide engineered to act simultaneously on three receptors: the glucose-dependent insulinotropic polypeptide (GIP) receptor, the glucagon-like peptide-1 (GLP-1) receptor, and the glucagon receptor. It is sometimes described as a “triple G” agonist.
As a next-generation incretin research molecule, it remains in clinical investigation and is studied for its combined multi-receptor pharmacology.
Retatrutide engages GIP, GLP-1, and glucagon receptors, all class B GPCRs. The glucagon-receptor component is investigated for its potential contribution to energy expenditure and hepatic lipid handling in preclinical models, complementing the glucose- and appetite-related effects associated with GIP and GLP-1 activation.
Triple receptor signaling — studied for balanced agonism across GIP, GLP-1, and glucagon receptors [1].
Body weight models — investigated in phase 2 obesity research measuring body weight change [2].
Glucose regulation — examined in type 2 diabetes trials measuring glycemic markers [1].
Hepatic lipid research — evaluated in studies of liver fat content [3].
📋 How published studies were conducted — a research reference summarizing study designs from the literature. This is not usage, dosing, or administration guidance. K4 Elite does not provide dosing instructions; determining any research protocol is the sole responsibility of the qualified researcher.
In a phase 2 trial, adults with obesity received retatrutide and investigators measured percentage change in body weight over 48 weeks [2]. In a separate phase 2 study, participants with type 2 diabetes received the compound and researchers measured HbA1c and body weight [1].
An exploratory analysis measured hepatic fat fraction by imaging in participants with metabolic dysfunction-associated steatotic liver disease [3].
Combinations examined in the research literature. Descriptive only — not a recommendation to combine compounds.
TirzepatideNeutral
Both are incretin-based multi-agonists studied within the same research pipeline; compared rather than combined.
SemaglutideNeutral
Shares GLP-1 pharmacology; typically evaluated as a comparator in trials.
InsulinCaution
Researchers note the glucagon-receptor component may influence glucose dynamics in study designs.
CagrilintideNeutral
Distinct amylin target; no established combined pharmacology.
Citations below are retrieved automatically from PubMed (NIH / U.S. National Library of Medicine) for the search term “Retatrutide”, newest first. They are listed as literature references for research purposes only. K4 Elite does not summarise, interpret or endorse their findings.
It is a triple agonist acting on GIP, GLP-1, and glucagon receptors, distinguishing it from single- and dual-agonist peptides.
What is its development status?
It is investigational and studied in clinical trials; it is described here as emerging research.
Is a verified PubChem CID available?
A specific PubChem CID was not confirmed by name at the time of writing; the published molecular formula is listed for reference.
Is this material for human use?
No. It is supplied for in-vitro and laboratory research use only, not for human or veterinary use.
Disclaimer: This profile summarizes published preclinical and laboratory research for reference only. It is not medical advice and makes no claim of safety or efficacy in humans. Determining any research protocol is the sole responsibility of the qualified researcher. Products are sold strictly for in-vitro research and have not been evaluated by the FDA.
K4 Elite